USANA Health (USNA) Loses 16.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
USANA Health Sciences (USNA) has seen its stock decline by 16.8% over the past four weeks, reaching oversold territory with a Relative Strength Index (RSI) of 29.62. This technical indicator, coupled with a 2.6% increase in consensus EPS estimates by analysts over the last 30 days and a Zacks Rank #1 (Strong Buy), suggests that the stock is poised for a potential trend reversal and rebound.
Each book sale funds 40 meals as USANA CEO pushes daily habits
USANA CEO Kevin Guest is advocating for a shift from health awareness to daily execution on World Health Day, emphasizing that consistent routines and small daily actions are crucial for long-term health. Guest highlights his book, "All the Right Reasons," whose proceeds fund meals through the USANA Foundation, with each book providing 40 meals. The foundation has already delivered over 112 million meals and aims to feed 20,000 families by the end of 2026.
Major USANA (USNA) holder Wentz updates 40.1% ownership via Gull Global
Gull Global Limited and Dr. Myron W. Wentz have reported a beneficial ownership of 7,408,345 shares of USANA Health Sciences (USNA) common stock, representing 40.1% of the outstanding shares. This ownership is held directly by Gull Global, with Dr. Wentz being considered a beneficial owner through a Bahamas-based trust. The filing details a history of transactions, including sales for liquidity and charitable donations, with no transactions reported in the 60 days before this amendment.
Vanguard (USNA) amendment shows 0 shares; subsidiaries report separately
The Vanguard Group has filed an amended Schedule 13G/A for USANA Health Sciences Inc (USNA), reporting 0 shares and 0% beneficial ownership following an internal realignment effective January 12, 2026. This change is in accordance with SEC Release No. 34-39538, which allows certain Vanguard subsidiaries to now report their ownership separately. The filing confirms that Vanguard no longer holds direct beneficial ownership over USNA securities and that no other single entity holds more than 5% interest.
Tested, Trusted, Approved: USANA CellSentials Earns ConsumerLab.com Seal of Approval for Purity and Potency
USANA's flagship CellSentials supplement has received the ConsumerLab.com Seal of Approval, signifying its adherence to rigorous standards for purity, potency, and label accuracy. This third-party verification provides customers with confidence in the product's quality, which is designed to bridge nutritional gaps and support overall wellness with over 40 essential vitamins, minerals, and antioxidants. The CellSentials also feature USANA's patented InCelligence Complex, including the new ingredient PQQ, for enhanced cellular and cognitive support.
Tested, Trusted, Approved: USANA CellSentials Earns ConsumerLab.com Seal of Approval for Purity and Potency
USANA's flagship CellSentials supplement has received the ConsumerLab.com Seal of Approval for its purity, potency, and label accuracy after undergoing independent testing. The product delivered stated nutrient levels and passed all contaminant screenings, reinforcing USANA's commitment to quality. The formula now also includes PQQ for mitochondrial support, enhancing its comprehensive cellular health benefits.
Insider Selling: USANA Health Sciences (NYSE:USNA) Director Sells 1,058 Shares of Stock
USANA Health Sciences (NYSE:USNA) Director Gilbert Fuller sold 1,058 shares of company stock on March 20th, 2026, for a total of $17,986.00 at an average price of $17.00 per share. The stock traded down to $16.88, near its 52-week low, despite the company beating quarterly EPS expectations. Institutional investors hold over 54% of the shares, and analyst ratings are mixed.
Fuller sells USANA [USNA] shares worth $17986
Director Gilbert A Fuller sold 1,058 shares of USANA Health Sciences Inc (NASDAQ: USNA) for $17,986 on March 20, 2026, leaving him with 0 shares. This sale happened while USANA's stock is near a 52-week low and is considered undervalued by InvestingPro. The company also updated its financial outlook, projecting net sales of approximately $925 million for fiscal year 2025 and between $925 million and $1 billion for 2026, despite an expected decline in its core nutritional business.
USANA (USNA) director Gilbert Fuller sells 1,058 shares, now holds none
USANA Health Sciences director Gilbert A. Fuller sold 1,058 shares of common stock at $17.00 per share in an open-market transaction on March 20, 2026. Following this sale, Fuller no longer directly owns any shares of USANA common stock. The transaction was reported via an SEC Form 4 filing, indicating a disposition of securities.
USANA Health Sciences: $925.3M Revenue, $0.58 Diluted EPS in 10-K
USANA Health Sciences reported consolidated net sales of $925.3 million for the year, primarily due to the Hiya acquisition, but diluted EPS declined to $0.58. The company's net earnings were $11.5 million, significantly down by 74.4% year-over-year, impacted by lower operating margins and a higher effective tax rate. Despite a decline in core active customers, the company expanded its revenue channels through an omni-channel model and the Hiya acquisition, which added 181.7 thousand monthly subscribers.
USANA (NYSE: USNA) outlines 2025 sales, China exposure and Hiya expansion
USANA Health Sciences (NYSE: USNA) reported 2025 net sales of $925 million, detailing its operations across core nutritional and the Hiya direct-to-consumer segments. Mainland China remains USANA's largest market, contributing 41.3% of net sales, while the company focuses on expanding its Hiya brand and omni-channel distribution. Key growth strategies include enhancing its Brand Partner Compensation Plan, accelerating product innovation, and addressing regulatory challenges, particularly in China.
USANA Health (USNA) Loses 16.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
USANA Health (USNA) has seen a 16.8% decline over the past four weeks, making it oversold according to the Relative Strength Index (RSI) with a reading of 29.62. This technical indicator, coupled with a 2.6% increase in consensus EPS estimates by Wall Street analysts over the last 30 days and a Zacks Rank #1 (Strong Buy), suggests a potential trend reversal and rebound for the stock.
USANA outlines 4% sales growth target for 2026 amid omnichannel and product innovation push
USANA Health Sciences is targeting a 4% sales growth by 2026, aiming for $1.02 billion in net sales, through a strategic focus on expanding its omnichannel ecosystem and introducing new product categories. The company is investing in digital tools and personalized healthcare solutions to enhance customer experience and drive growth in key markets. This initiative follows a period of flat sales, and the outlined strategy is expected to reignite the company's financial performance.
5 Low P/B Ratio Stocks That You May Consider Buying in March
This article identifies five low Price-to-Book (P/B) ratio stocks that investors might consider for March, highlighting the P/B ratio as a key metric for identifying undervalued stocks with growth potential. It explains how to calculate book value and the P/B ratio, discussing its benefits and limitations. The article also outlines specific screening parameters used and provides details on the five selected companies: Ford Motor (F), USANA Health Sciences (USNA), Strategic Education (STRA), Patria Investments Limited (PAX), and Concentrix (CNXC).
USANA Health Sciences Hits 52-Week Low at $18.04 Amid Ongoing Struggles
USANA Health Sciences, Inc. has reached a new 52-week low of $18.04, reflecting a significant 61.16% stock price decline over the past year. The microcap company has reported negative results for seven consecutive quarters, with decreasing operating cash flow and net profit. This underperformance highlights the financial challenges USANA is currently facing compared to the broader market.
USANA Health Sciences Experiences Valuation Adjustment Amidst Competitive Market Dynamics
USANA Health Sciences, a microcap company in the Pharmaceuticals & Biotechnology sector, has recently adjusted its valuation, with its stock price at $21.52. The company's stock has declined by nearly 25% over the past year, contrasting with the S&P 500's positive performance, indicating challenges within a competitive market. Key financial metrics like a P/E ratio of 21 and an EV to EBITDA ratio of 5.70 are highlighted for comparison with industry peers.
USANA (USNA) COO exercises 7,422 RSUs and withholds 3,144 shares for taxes
USANA Health Sciences' COO, Walter Noot, exercised 7,422 restricted stock units (RSUs) on February 27, 2026, converting them into common stock. Following this, 3,144 shares were disposed of at $21.52 per share to cover tax obligations. After these transactions, Noot directly holds 9,256 shares of USANA common stock and retains 75,130 RSUs.
USANA Health (USNA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
USANA Health Sciences (USNA) recently formed a hammer chart pattern after a 9.1% stock loss, indicating a potential reversal and support. This technical sign, combined with rising optimism from Wall Street analysts and a Zacks Rank #1 (Strong Buy), suggests that the stock is poised for a turnaround due to improving earnings estimates. Investors are advised to consider these factors for a potential trend reversal.
USANA (USNA) executive converts RSUs, withholds 1,349 shares for tax
USANA Health Sciences Chief People Officer Paul A. Jones reported exercising 4,596 restricted stock units (RSUs) on February 27, which converted into common stock. Concurrently, 1,349 common shares were withheld to cover tax obligations. After these transactions, Jones directly holds 46,611 RSUs and 12,374 shares of common stock.
USANA (USNA) CIO Benedict sells 4,553 shares in open-market trade
USANA Health Sciences' Chief Information Officer, Peter Benedict, sold 4,553 shares of the company's common stock in an open-market transaction. The shares were sold at a weighted average price of $19.3848, ranging from $19.29 to $19.415. Following this transaction, Benedict reported owning no shares of USANA common stock directly.
Usana Health Sciences CIO Benedict Peter sells $88,258 in stock
Usana Health Sciences Chief Information Officer Benedict Peter sold 4,553 shares of company stock for a total of $88,258. Following this transaction, Peter directly owns no shares in the company. USANA Health Sciences also announced financial projections for 2025 and 2026, including expected net sales and a continued partnership with the Jamaica Bobsleigh and Skeleton Federation.
USANA Health Sciences to Participate in Upcoming Investor Conferences
USANA Health Sciences, Inc. (NYSE: USNA) announced its participation in two upcoming investor conferences: the Sidoti Small-Cap Virtual Conference on March 18-19, 2026, and the 38th Annual ROTH Conference on March 23, 2026. The company will engage in fireside chats, one-on-one meetings, and relevant webcasts will be available on their investor relations website.
USANA Health Sciences (USNA) CFO exercises RSUs, disposes shares for taxes
USANA Health Sciences CFO, IIEKKING G DOUG, exercised 7,469 Restricted Stock Units (RSUs) on February 27, 2026, converting them into common shares. The CFO then sold 5,031 common shares at $21.52 per share to cover tax obligations, resulting in a direct holding of 5,360 common shares after the transactions. The RSUs vest 25% on the anniversary of February 27, 2025.
USANA Health Sciences to Participate in Upcoming Investor Conferences
USANA Health Sciences (NYSE: USNA) announced its participation in two upcoming investor conferences: the Sidoti Small-Cap Virtual Conference from March 18-19, 2026, and the 38th Annual ROTH Conference on March 23, 2026. A live webcast of the Sidoti fireside chat will be available on the company's investor relations website. USANA manufactures and sells nutritional supplements, functional foods, and personal care products globally, and holds controlling stakes in Hiya Health Products and Rise Wellness.
USANA Health Sciences to Participate in Upcoming Investor Conferences
USANA Health Sciences, Inc. (NYSE: USNA) announced its participation in two upcoming investor conferences. The company will attend the Sidoti Small-Cap Virtual Conference from March 18-19, 2026, featuring a fireside chat and one-on-one meetings, and the 38th Annual ROTH Conference on March 23, 2026, for one-on-one meetings. A live webcast of the Sidoti fireside chat will be available on USANA's investor relations website.
How a CEO links leadership reading to meals for hungry children
USANA Chairman & CEO Kevin Guest promotes disciplined reading as a key leadership tool during National Reading Month, emphasizing its role in improving decision-making, communication, and innovation. He has asked USANA management to adopt book-based practices. Proceeds from Guest's book, "All the Right Reasons," fund the USANA Foundation's meal programs, which have provided over 112 million meals to hungry children.
USANA Chairman & CEO Kevin Guest Urges Leaders to Use Reading as a Competitive Advantage in National Reading Month
USANA Chairman & CEO Kevin Guest emphasizes the importance of disciplined reading as a competitive advantage for leaders, especially during National Reading Month. He argues that reading enhances leadership skills such as critical thinking, communication, and decision-making, while also strengthening character and fostering innovation. Guest has integrated this philosophy into USANA's culture, encouraging his management team to apply lessons from books like "Made to Stick" to their work.
USANA (USNA): Buy, Sell, or Hold Post Q4 Earnings?
USANA (USNA) stock has seen a significant 32.2% drop, trading at $21.47, leading investors to question its future. Analysts identify declining revenue, limited distribution channels, and falling earnings per share as key concerns, recommending other opportunities over USANA despite its fair valuation. The article suggests that while USANA is not a terrible business, it's not a top pick due to better alternatives in the market.
USNA Financials: Income Statement, Balance Sheet & Cash Flow
Usana Health Sciences Inc (USNA) experienced a 7.2% revenue decline in fiscal year 2024, reaching $854.5M, with net income falling 34.1% to $42.0M. Despite the revenue challenges and decreased profitability metrics like operating margin and return on equity, the company maintains a strong balance sheet with low debt-to-equity and a safe Altman Z-Score, indicating low bankruptcy risk. USNA also exhibits high earnings quality (1.45x cash-backed) and robust interest coverage (236.0x), even as its overall financial health score is moderate at 45/100.
Usana’s Rise Wellness announces launch of Protein Pop Plus at Costco nationwide
Usana's Rise Wellness has launched Protein Pop Plus, a new carbonated, ready-to-drink clear protein beverage, now available nationwide at all 607 Costco locations in the United States. This expansion builds on the success of their original Protein Pop line, offering consumers another option for high-protein nutrition in a refreshing format. Rise Wellness is a wholly owned subsidiary of Usana Health Sciences (USNA).
USANA (USNA) chief scientific officer receives 24,526 restricted stock units
USANA Health Sciences (USNA) chief scientific officer, Kathryn Michelle Armstrong, was granted 24,526 restricted stock units on February 19, 2026. This grant increases her beneficial ownership to 44,782 restricted stock units, with each unit representing a contingent right to one share of USANA common stock. The units will vest in four equal 25% installments on February 19 of each year following the grant date.
Protein Pop Launches Protein Pop Plus at Costco Nationwide
Rise Wellness has launched "Protein Pop Plus" at all 607 Costco locations across the United States. This new carbonated, clear protein beverage offers 30 grams of protein, a blend of whey protein isolate and bovine collagen, zero sugar, and no artificial sweeteners or caffeine. The expansion follows the successful debut of the original Protein Pop at Natural Products Expo West and its subsequent launch in Target stores, solidifying the brand's position in the functional beverage market.
USANA Health (NYSE: USNA) grants COO 41,373 restricted stock units
USANA Health Sciences' Chief Operating Officer, Walter Noot, was granted 41,373 restricted stock units (RSUs) on February 19, 2026. These RSUs will vest 25% annually on February 19th, increasing his direct holdings to 82,552 restricted stock units. This grant aligns his compensation with the company's long-term performance and is detailed in a Form 4 SEC filing.
USANA (USNA) Chief People Officer awarded 25,622 restricted stock units
USANA Health Sciences' Chief People Officer, Paul A. Jones, was granted 25,622 restricted stock units on February 19, 2026. These units represent a contingent right to receive one share of USANA common stock each and will vest in four equal installments annually. Following this award, Jones now directly holds 51,207 restricted stock units.
USANA (USNA) legal chief sells stock while receiving 36,662 RSUs
USANA Health Sciences' Chief Legal Officer, Joshua Foukas, executed two significant transactions. He acquired 36,662 restricted stock units (RSUs) on February 19, 2026, increasing his total RSU holdings to 73,270. The following day, February 20, 2026, Foukas sold 4,461 shares of common stock at an average price of $21.345 per share, leaving him with zero directly held common stock.
Insider Selling: USANA Health Sciences (NYSE:USNA) Insider Sells 4,461 Shares of Stock
USANA Health Sciences (NYSE:USNA) insider Joshua Foukas sold 4,461 shares of the company's stock for a total of $95,197.74. The sale occurred on February 20th at an average price of $21.34 per share. This follows USANA reporting Q earnings of $0.60 EPS, beating estimates, but with slim net margins and modest ROE.
Insider Sell Alert: Joshua Foukas Sells 4,461 Shares of Usana He
Joshua Foukas, Chief Legal Officer of Usana Health Sciences Inc (USNA), recently sold 4,461 shares, bringing his total ownership to zero. This transaction is part of a pattern observed over the past year, with 19 insider sells and no buys. Despite the insider selling, Usana Health Sciences Inc is currently trading at $21.35, significantly undervalued with a price-to-GF-Value ratio of 0.44 compared to its GF Value of $48.96.
Usana Health Sciences: Chief legal officer Foukas sells $95k in shares
Joshua Foukas, Chief Legal Officer of Usana Health Sciences (NASDAQ: USNA), sold 4,461 shares of common stock for approximately $95,220. Following the sale, Foukas directly holds zero shares, but was granted 36,662 restricted stock units which vest quarterly starting February 19, 2026. This comes as the company projects 2025 net sales of $925 million and 2026 revenues between $925 million and $1 billion, alongside an extended partnership with the Jamaica Bobsleigh and Skeleton Federation.
USANA Partners with World-Famous Jamaican Bobsled Team to Help Fuel Their Olympic Dreams
USANA Health Sciences has partnered with the Jamaica Bobsleigh and Skeleton Federation (JBSF) through the 2026 Winter Olympics, providing nutritional products to help the team perform at their best. The JBSF chairman and CEO, Nelson "Chris" Stokes, expressed trust in USANA due to its commitment to clean sport and product efficacy. USANA's chief commercial officer, Brent Neidig, anticipates the partnership will be a big success for both parties, highlighting the benefits of USANA products for athletes across various sports.
USANA Health Sciences (NYSE:USNA) Rating Increased to Buy at Wall Street Zen
Wall Street Zen has upgraded USANA Health Sciences (NYSE:USNA) from a "hold" to a "buy" rating, despite the MarketBeat consensus remaining "Reduce" with an average target price of $36.00. The company recently reported an earnings beat with EPS of $0.60 against an expected $0.41 and revenue of $226.2 million. However, USANA maintains a modest net margin of 1.16%, a P/E ratio of approximately 39.4, and institutional ownership stands at about 54.25%.
USANA Health Sciences, Inc. (NYSE:USNA) Q4 2025 Earnings Call Transcript
USANA Health Sciences (NYSE:USNA) held its Q4 and fiscal year 2025 earnings call, with CEO Kevin Guest returning to lead the company's next phase of growth. The company is focusing on strategic pillars like scientific excellence, operational discipline, and an aligned global sales force, aiming for a 4% net sales growth at midpoint for fiscal 2026. Key initiatives include expanding omnichannel reach, advancing product innovation, accelerating technology modernization, and driving growth in its venture companies, Rise Wellness and Hiya.
USANA (USNA) Q4 2025 Earnings Call Transcript
USANA Health Sciences (NYSE:USNA) released its Q4 2025 earnings call transcript, detailing a strategic shift towards a science-driven, omnichannel nutrition company. The company projects 4% net sales growth for fiscal 2026, driven by new retail partnerships and expansion of brands like Rise Wellness and HYA, despite anticipating continued high effective tax rates and margin pressures. Executives discussed efforts to modernize technology, streamline operations, and diversify revenue streams beyond traditional direct selling and the Chinese market.
USANA (USNA) Q4 2025 Earnings Call Transcript
USANA Health Sciences (USNA) held its Q4 2025 earnings call, discussing a strategic shift towards a science-driven, omnichannel nutrition company with a projected 4% net sales growth for fiscal year 2026. This growth is primarily expected to come from its Rise Wellness and HYA brands, which are expanding their retail presence in major stores like Costco and Target, and internationally. The company also announced a 10% headcount reduction to achieve $10 million in annualized SG&A savings and highlighted ongoing challenges with a high effective tax rate due to geographic misalignment of revenues and costs.
USANA Reports Fiscal Q4 and Full Year 2025 Financial Results
USANA Health Sciences, Inc. announced its financial results for fiscal Q4 and the full year 2025, reporting net sales of $925 million, an 8% year-over-year improvement. The company saw stabilization in active customer counts in its core nutritional business and strong growth in its omnichannel brands, Hiya and Rise, as part of a diversification strategy. USANA projects consolidated net sales between $925 million and $1 billion for fiscal year 2026.
USNA Q4 Deep Dive: Omnichannel Push and Brand Expansion Shape Outlook Amid Margin Pressures
USANA Health Sciences (USNA) met Q4 CY2025 revenue expectations and significantly beat non-GAAP profit estimates, yet the market reacted negatively due to ongoing margin pressures and a shift towards lower-margin brands. The company is focusing on an omnichannel strategy, new product initiatives, and technology investments, including AI, to drive future growth despite acknowledging continued gross margin headwinds. Key areas of focus for upcoming quarters include the expansion pace of new brands (Hiya, Rise Wellness) and the effectiveness of technology upgrades and cost discipline in stabilizing margins.
USANA Health Sciences (NYSE:USNA) Upgraded by Zacks Research to Hold Rating
Zacks Research upgraded USANA Health Sciences (NYSE:USNA) from a "strong sell" to a "hold" rating, though other analysts like Weiss Ratings maintain a "sell" rating. The company recently reported better-than-expected earnings, with $0.60 EPS against an anticipated $0.41, and revenue of $226.2 million. Despite mixed analyst views, institutional ownership remains significant, and several funds have increased their positions in the stock.
Usana reports Q4 EPS 60c vs. 64c last year
Usana (USNA) reported Q4 EPS of 60 cents, down from 64 cents last year, despite achieving Q4 revenue of $226.2 million, an increase from $213.6 million in the prior year. The company's Chairman and CEO, Kevin Guest, noted stabilization in active customer counts in the core nutritional business, with modest sequential growth led by markets like mainland China, the United States, and Canada, while omnichannel brands Hiya and Rise also showed solid year-over-year growth.
USANA Health Sciences (NYSE:USNA) Releases Earnings Results, Beats Estimates By $0.19 EPS
USANA Health Sciences (NYSE:USNA) reported quarterly earnings of $0.60 per share, surpassing analyst estimates of $0.41 by $0.19. Despite beating estimates, the company's shares fell to $20.61 on Tuesday, with a market capitalization of $376.75 million. Analysts maintain a consensus "Reduce" rating for the stock, with an average price target of $36.00.
USANA HEALTH SCIENCES ($USNA) Releases Q4 2025 Earnings, Stock Rises
USANA Health Sciences ($USNA) reported its Q4 2025 earnings, with earnings per share of $0.60, beating analyst estimates by $0.18. However, the company's revenue of $226.2 million missed estimates. Following the announcement, the stock price rose by 2.63%, and the article also details recent insider trading activity and hedge fund movements related to USNA.
USANA Health: Fourth Quarter Earnings Overview
USANA Health Sciences reported a net loss of $1.8 million, or $0.10 per share, for the fourth quarter, with adjusted earnings of $0.60 per share and revenue of $226.2 million. For the full year, the company achieved a net income of $10.8 million ($0.58 per share) on $925.3 million in revenue. Looking ahead, USANA projects full-year earnings per share between $1.95 and $2.29 and revenue between $925 million and $1 billion.
